



Request For Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE,
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	10/091,284
Filing Date	March 5, 2002
First Named Inventor	Duncan Roger HARPER, et al
Group Art Unit	1712
Examiner Name	R. Lovering
Attorney Docket Number	08291-719001

This is a Request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

- Submission required under 37 C.F.R. §1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s)

 - ☐ Previously submitted. If a final Office action is outstanding, any amendment filed after the final Office action may be considered as a submission even if this box is not checked.
 - ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
 - ☐ Other _____
 - ☒ Enclosed
 - ☒ Amendment/Reply
 - ☐ Affidavit(s)/Declaration(s)
 - ☐ Information Disclosure Statement (IDS)
 - ☒ Other Petition for Extension of Time
- Miscellaneous**

 - ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. §1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. §1.17(i) required)
 - ☐ Other _____
- Fee** The RCE fee under 37 C.F.R. §1.17(e) is required by 37 C.F.R. §1.114 when the RCE is filed.

 - ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 06-1050
 - ☒ RCE fee required under 37 CFR 1.17(e)
 - ☒ Extension of time fee (37 CFR 1.136 and 1.17)
 - ☒ Other Any deficiencies
 - ☐ Check in the amount of \$ _____ enclosed
 - ☐ Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED

Name (Print/Type)	Frederick H. Rabin	Registration No. (Attorney/Agent)	24,488
Signature		Date	November 3, 2004

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Maria A. Gillis	Date	November 3, 2004
Signature			



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Duncan Roger HARPER, et al. Art Unit : 1712
Serial No. : 10/091,284 Examiner : R. Lovering
Filed : March 5, 2002
Title : AEROSOL COMPOSITIONS TO WHICH AN ELECTROSTATIC CHARGE
CAN BE IMPARTED UPON ACTUATION

MAIL STOP RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. § 1.114

S I R:

This amendment is in response to the office action of 3 June 2004 and is intended to serve as Submission accompanying a Request for Continued Examination.

Applicants are amending paragraphs 0029, 0030 and 0031 of the written description. These amendments are on the following pages 2 and 3.

A listing of all of the claims in this application, including the text of all pending claims, appears on pages 4-10. Claims 1 and 3-16 are being cancelled. Claims 17 and 20-23 are being amended. Claims 25-36 are newly presented claims.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

3 November 2004
Date of Deposit
Signature *Maria A. Gillis*
Maria A. Gillis
Typed or Printed Name of Person Signing Certificate

AMENDED PARAGRAPHS IN THE WRITTEN DESCRIPTION:

[0029] The polar or ionic or aromatic or conjugated compound which is included as component (d) in the compositions of the present invention is preferably a compound which is attracted to the interface between the disperse phase and the continuous phase and may be selected from:

a) (I) alkali metal salts, alkaline earth metal salts, ammonium salts, amine salts or amino alcohol salts of one or more of the following compounds: alkyl sulphates, alkyl ether sulphates, alkylamidoether sulphates, alkylaryl polyether sulphates, monoglyceride sulphates, polyglyceride sulphates, alkyl sulphonates, alkylamine sulphonates, alkyl-aryl sulphonates, olefin sulphonates, paraffin sulphonates, alkyl sulfo-succinates sulphosuccinates, alkylether sulphosuccinates, alkylamide sulphosuccinates, alkyl sulphocinnamates, alkyl sulphoacetates, alkyl phosphates, alkylether phosphates, acyl sarcosinates, acyl isothionates and N-acyl taurates;

b) (II) alkyl amidopropylbetaines, ~~alkylamido betaines~~ alkylamidobetaines, alkylamidosulphobetaines, alkylbetaines, aminimides, quaternary ammonium compounds and quaternary phosphonium compounds;

e) (III) carboxylic acids, carboxylic acid salts, esters, ketones, aldehydes, amides or amines of carboxylic acids containing from 6 to 30 carbon atoms; and

d) (IV) diethyl orthophthalate, methylphenylcarbiny acetate, α -methyl ionone, 4-hydroxy-3-methoxy-benzaldehyde, phenylethyl alcohol, dipropylene glycol, styryl acetate, n-butyl benzoate, isopropyl-4-hydroxybenzoate, isobutyl acetophenone, isopropyl acetophenone, nicotinic acid, benzoic acid, 2-naphthol, neopentyl benzene, naphthalene, toluene, fullerene, tannic acid, t-butylacetophenone, ~~isopropylcinnamate~~ isopropylcinnamate, resorcinol, 4-methoxycinnamaldehyde ~~4-methoxycinnamaldehyde~~, arbutin, 4-acetoxy-3-methoxycinnamaldehyde, 4-isopropylphenol, trans-stilbene, esculetin, p-chloro-m-xyleneol,

chloro-o-cresol, triclosan, norfenefrine, norepinephrine, hexyl-resorcinol, limonene, methylphenylcarbinyl acetate, and p-tert-butyl- α -methylhydrocinnamic aldehyde.

[0030] Particularly preferred compounds in group (b) (II) are alkyltrimethylbenzylammonium chloride, ~~cetyltrimethylammonium~~ octyltrimethylammonium bromide, cetyltrimethylammonium bromide and dodecyltrimethylphosphonium bromide.

[0031] Particularly preferred compounds in group (c) (III) are lauric, oleic, palmitic, ricinoleic and stearic acids, or the salts, amides, esters, ketones or aldehydes thereof.